Europeanhhm
BD - Earth day 2024

Aiosyn, Radboudumc, and Pathologie-DNA are awarded a EUR 1.3M EFRO grant to develop AI-powered solutions for cancer diagnostics

Wednesday, May 10, 2023

Aiosyn, a medical software company that develops AI-powered pathology solutions, has been awarded a EUR 1.300.000 EFRO-OOST grant alongside Radboud university medical center and Pathologie-DNA to accelerate the development of AI technology for breast and skin cancer diagnostics. With the AIRAT project, the three organizations will join forces to introduce CE-marked deep learning algorithms for automated mitosis detection to the market.

Close to 20 million patients are diagnosed with cancer every year (1). Unfortunately, incidence is expected to increase in the upcoming decades, with a predicted global burden of about 30 million new cancer cases per year by 2040 (2). This underlines the need for new tools to improve the efficiency and accuracy of the disease diagnosis and treatment.

As part of this project, Aiosyn will further develop and validate AI-powered algorithms for breast and skin cancer diagnosis. One of such algorithms is Aiosyn’s solution for automated mitosis detection. The quantification of mitotic figures in cancer tissue is an essential part of the diagnosis of multiple tumor types. By leveraging AI-based digital biomarkers, pathologists can more accurately predict tumor growth and understand patient prognosis. This will help reduce observer variability, improve the accuracy and consistency of diagnoses, and ultimately enhance patient outcomes.

Jeroen van der Laak, professor at Radboud university medical center and CSO of Aiosyn: “Once you have decided which problem to solve, and have collected all required data, developing AI for Pathology is doable. But collecting high-quality data is tough, and getting the AI to a level that truly creates patient value is even tougher. In our AIRAT project we will tackle those challenges: collect multi-center data and move the developed AI forward to a certified product, ready to support pathologists.”

Aiosyn’s algorithms will be fully integrated in existing digital pathology workflows such as Sectra. The AI-powered solutions will aim to provide major progress in the assessment and disease management of cancer patients worldwide.

“We are excited to partner with Aiosyn and Radboud UMC on this project,” said Matthijs van Oosterhout, on behalf of Pathologie-DNA, chairman of Pathologie-DNA B.V. “Together, we can leverage our respective strengths to develop AI solutions that will improve patient outcomes and advance the field of pathology. This collaboration is a great example of how start-ups and established companies can work together to drive innovation.”

Source: aiosyn.com
 

The Healthcare Patient Experience & Engagement Summit 2024Healthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO Summit